Objective To assess the efficacy of telbivudine in the treatment of chronic hepatitis B (CHB).
Methods Randomized controlled trials (RCTs) of telbivudine therapy vs. lamivudine therapy in both Chinese and English were retrieved from seven electronic databases with a cut-off date in February 2010, including PubMed, EMbase, VIP, CBM, CNKI, and The Cochrane library. The meta-analyses and evaluation on methodology quality were performed for the included studies. Results Two RCTs as Grade-A study were included. The meta-analyses showed that telbivudine was superior to lamivudine in aspects of therapeutic response (RR=1.28, 95%CI 1.10 to 1.48, P=0.001), ALT normalization (RR=1.12, 95%CI 1.01 to 1.23, P=0.02), and PCR-negative HBV DNA or below the lower limit (RR=1.44, 95%CI 1.36 to 1.53, P lt;0.000 01), primary treatment failure (OR=0.28, 95%CI 0.18, to 0.43, P lt;0.000 01), viral breakthrough (OR=0.38, 95%CI 0.32 to 0.47, P lt;0.000 01) and viral resistance (OR=0.44, 95%CI 0.36 to 0.55, P lt;0.000 01).
Conclusion Based on the current clinical evidence, telbivudine demonstrates superiority in comparison with lamivudine on all direct measures of antiviral efficacy for CHB. Because of the short follow-up duration and the small sample size of the included studies, it is expected to further discuss the long-term efficacy.
Citation： ZHAN Mei,WU Fengbo,WU Bin,LIU Ruming,TANG Yao. Telbivudine in the Treatment of Chronic Hepatitis B: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2011, 11(1): 101-105. doi: 10.7507/1672-2531.20110018 Copy
-
Previous Article
新春寄语 -
Next Article
Research Progress on Diet and Heart Failure